Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

AdaptHealth (AHCO) Shares Repurchased (2022 - 2023)

AdaptHealth's quarterly Shares Repurchased came in at $20.1 million in Q4 2023, up 117.38% quarter-over-quarter from $9.2 million in Q1 2023.

AdaptHealth has reported Shares Repurchased for 2 years, with the latest figure at $20.1 million in Q4 2023.

  • For the quarter ending Q4 2023, Shares Repurchased changed N/A year-over-year to $20.1 million; the trailing twelve-month figure through Sep 2024 stood at $20.1 million (up 117.38% YoY), and the FY2023 full-year result was $29.3 million, up 109.23% from the prior year.
  • Shares Repurchased for Q4 2023 stood at $20.1 million, up from $9.2 million in the prior quarter.
  • The five-year high for Shares Repurchased was $20.1 million in Q4 2023, with the low at $3.4 million in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Repurchased (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 180.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 105.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 421.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 100.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 74.30 Mn
10 AdaptHealth 1.35 Bn 1.31 Bn 111.50 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 20.05 Mn
Dec 31, 2023 20.05 Mn
Mar 31, 2023 9.22 Mn
Mar 31, 2023 9.22 Mn
Sep 30, 2022 10.62 Mn
Sep 30, 2022 10.62 Mn
Jun 30, 2022 3.38 Mn
Jun 30, 2022 3.38 Mn